U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. FACTA Farmaceutici S.p.A. - 08/25/2017
  1. Warning Letters

CLOSEOUT LETTER

FACTA Farmaceutici S.p.A.

Recipient:
FACTA Farmaceutici S.p.A.

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

August 25, 2017

Davide Gullua
Quality Unit Director
FACTA Farmaceutici S.p.A.
Nucleo Ind. Le S. Atto
San Nicolo a Tordino 64100 (TE), Italy

Reference: Warning Letter 320-17-17

Location: FACTA Farmaceutici S.p.A.
Zona Industriale Sant’ Atto S N
Terramo, Teramo, 64100, Italy

Dear Mr. Gullua:

The Food and Drug Administration has completed an evaluation of FACTA Farmaceutici S.p.A. (FEI 3006028606) corrective actions in response to Warning Letter 320-17-17, dated January 01, 2017. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any questions regarding this letter, you may contact me at the above address or number: (301) 796-5339.

For more information on the U.S. FDA, please visit our website at www.fda.gov.
 

Sincerely,
/S/

Cesar E. Matto
Compliance Officer
Division of Drug Quality

Back to Top